Company intelligence / Profile preview

GenePlus

Ownership: Private
Development stage: Other

Overview

GenePlus provides next-generation sequencing-based diagnostic solutions for oncology, pathogen detection, and hereditary disease screening. Their clinical laboratory has achieved CLIA qualification. They offer a range of NGS panels such as Oncology 188-Gene Variant Assay, Multi-Gene Variant Assay, Personalized MRD Assay, Hereditary Cancer Screen Assay. The company is active in strategic partnerships in precision oncology.

Therapeutic areas: Infectious DiseasesRare DiseasesOncology
Modalities: Next generation sequencing-based diagnosticsMolecular diagnostics assays
Industry: Molecular Diagnostics

Partnerships

Euroclone (strategic partnership in precision oncology)

Beyond the preview

Go deeper on GenePlus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenePlus.